An additional rescue dose of GnRH antagonist administered the day before hCG trigger is effective to prevent ovarian hyperstimulation syndrome (OHSS) in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes

An additional rescue dose of GnRH antagonist administered the day before hCG trigger is effective to prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN02750360

Enrollment

194

Registered

2014-08-13

Start date

2009-11-01

Completion date

Unknown

Last updated

2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian hyperstimulation syndrome (OHSS), ovarian stimulation, GnRH antagonist, IVF Pregnancy and Childbirth

Interventions

Patients were randomised to: 1. Intervention group A (down-regulate FSH daily dose to 100 iu, up until hCG trigger and receive double GnRH antagonist dose the day before hCG trigger) 2. Control group

Grossman et al., 2010). If these symptoms of OHSS were present, the embryo transfer was cancelled, all embryos were cryo-preserved at the stage of blastocyst. Patients in both groups, without signs of

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Patients age 18-40 years, at high risk for OHSS who underwent ovarian stimulation for in vitro fertilization (IVF) using the 6th day fixed GnRH antagonist protocol. Patients were considered at actual risk of developing moderate to severe OHSS when they had a high or rapidly rising serum estradiol (=3500 pg/ml before oocyte maturation and projected to be >4500 pg/ml the day of hCG administration) and 18 or more follicles =11 mm but without any mature follicle >16 mm appearing at that time. 2. With polycystic ovaries (The Rotterdam ESHRE/ASRM-sponsored PCOS consensus Workshop Group, 2004) 3. At high risk for OHSS 4. Not willing to cancel their IVF cycle

Exclusion criteria

Exclusion criteria: Polycystic ovarian syndrome (PCOS) patients

Design outcomes

Primary

Measure	Time frame
1. Early and late OHSS rates 2. Clinical pregnancy rate	—

Secondary

Measure	Time frame
1. Oestradiol (E2) 2. Luteizing hormone (LH) 3. Progesterone (PR) levels	—

Countries

Greece

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 9, 2026